<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Orca Capital AG -->
          <cik>0002052389</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/14/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001818844</issuerCik>
        <issuerName>Dogwood Therapeutics, Inc.</issuerName>
        <issuerCusip>92829J203</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>44 MILTON AVENUE</com:street1>
          <com:city>ALPHARETTA</com:city>
          <com:stateOrCountry>GA</com:stateOrCountry>
          <com:zipCode>30009</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Orca Capital AG</reportingPersonName>
      <citizenshipOrOrganization>2M</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>69821.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>69821.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>69821.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>3.7</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 1,911,128 shares of Common Stock outstanding immediately after giving effect to the completion of the Issuer's registered offering as described in the Issuer's Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on March 14, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Dogwood Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>44 Milton Ave, Alpharetta, GA 30009</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Orca Capital AG</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Sperlring 2 85276 Hettenshausen Deutschland</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Germany</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>69,821 shares of the Issuer's common stock, par value $0.001 per share</amountBeneficiallyOwned>
        <classPercent>3.7%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>69,821</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>69,821</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Orca Capital AG</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Thomas Konig</signature>
        <title>Thomas Konig/Director</title>
        <date>03/17/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
